Skip to main navigation Skip to search Skip to main content

Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium

  • Miguel García-Pardo
  • , Amy Chang
  • , Sabine Schmid
  • , Mei Dong
  • , M. Catherine Brown
  • , David Christiani
  • , Hilary Aurora Tindel
  • , Paul Brennan
  • , Chu Chen
  • , Jie Zhang
  • , Brid M. Ryan
  • , David Zaridze
  • , Matthew B. Schabath
  • , Leticia Ferro Leal
  • , Rui Manuel Reis
  • , Adonina Tardon
  • , Guillermo Fernández-Tardon
  • , Sanjay S. Shete
  • , Angeline Andrew
  • , Hermann Brenner
  • Wei Xu, Rayjean J. Hung, Geoffrey Liu

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: We explored the association of respiratory and cardiometabolic comorbidities with NSCLC overall survival (OS) and lung cancer-specific survival (LCSS), by stage, in a large, multicontinent NSCLC pooled data set. Methods: On the basis of patients pooled from 11 International Lung Cancer Consortium studies with available respiratory and cardiometabolic comorbidity data, adjusted hazard ratios (aHRs) were estimated using Cox models for OS. LCSS was evaluated using competing risk Grey and Fine models and cumulative incidence functions. Logistic regression (adjusted OR [aOR]) was applied to assess factors associated with surgical resection. Results: OS analyses used patients with NSCLC with respiratory health or cardiometabolic health data (N = 16,354); a subset (n = 11,614) contributed to LCSS analyses. In stages I to IIIA NSCLC, patients with respiratory comorbidities had worse LCCS (stage IA aHR = 1.51, confidence interval [CI]: 1.17–1.95; stages IB–IIIA aHR = 1.20, CI: 1.06–1.036). In contrast, patients with stages I to IIIA NSCLC with cardiometabolic comorbidities had a higher risk of death from competing (non-NSCLC) causes (stage IA aHR = 1.34, CI: 1.12–1.69). The presence of respiratory comorbidities was inversely associated with having surgical resection (stage IA aOR = 0.54, CI: 0.35–0.83; stages IB–IIIA aOR = 0.57, CI: 0.46–0.70). Conclusions: The presence of either cardiometabolic or respiratory comorbidities is associated with worse OS in stages I to III NSCLC. Patients with respiratory comorbidities were less likely to undergo surgery and had worse LCSS, whereas patients with cardiometabolic comorbidities had a higher risk of death from competing causes. As more treatment options for stages I to III NSCLC are introduced into the practice, accounting for cardiometabolic and respiratory comorbidities becomes essential in trial interpretation and clinical management.

Original languageEnglish (US)
Pages (from-to)313-323
Number of pages11
JournalJournal of Thoracic Oncology
Volume18
Issue number3
DOIs
StatePublished - Mar 2023

Keywords

  • Comorbidity
  • COPD
  • Early-stage
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

MD Anderson CCSG core facilities

  • Biostatistics Resource Group

Fingerprint

Dive into the research topics of 'Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium'. Together they form a unique fingerprint.

Cite this